BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Novartis
QuintilesIMS
Mallinckrodt
Fish and Richardson
Cerilliant
Federal Trade Commission
Cipla
Daiichi Sankyo
Johnson and Johnson

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,333,044

« Back to Dashboard

Which drugs does patent 6,333,044 protect, and when does it expire?

Patent 6,333,044 protects SPRIX and is included in one NDA.

This patent has nine patent family members in eight countries.
Summary for Patent: 6,333,044
Title: Therapeutic compositions for intranasal administration which include KETOROLAC.RTM.
Abstract:An analgesic/anti-inflammatory pharmaceutical dosage form which comprises an effective amount of an active ingredient selected from the group consisting of racemic 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, optically active forms thereof and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable excipient or diluent, said dosage form being an intranasally administrable dosage form.
Inventor(s): Santus; Giancarlo (Milan, IT), Bottoni; Giuseppe (Bergamo, IT), Bilato; Ettore (Padua, IT)
Assignee: Recordati, S.A. Chemical and Pharmaceutical Company (Chiasso, CH)
Application Number:08/383,707
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition; Formulation; Use; Delivery;

Drugs Protected by US Patent 6,333,044

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Egalet Us Inc SPRIX ketorolac tromethamine SPRAY, METERED;NASAL 022382-001 May 14, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,333,044

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI91A2024Jul 22, 1991

Non-Orange Book US Patents Family Members for Patent 6,333,044

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,267,827 Therapeutic compositions for intranasal administration which include KETOROLAC ➤ Subscribe
7,476,689 Therapeutic compositions for intranasal administration which include KETOROLAC ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,333,044

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 130758 ➤ Subscribe
Germany 69206345 ➤ Subscribe
Denmark 0524587 ➤ Subscribe
European Patent Office 0524587 ➤ Subscribe
Spain 2082288 ➤ Subscribe
Greece 3019012 ➤ Subscribe
Italy 1250691 ➤ Subscribe
Italy MI912024 ➤ Subscribe
Japan 3586735 ➤ Subscribe
Japan H05194215 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Farmers Insurance
Daiichi Sankyo
Express Scripts
Citi
Medtronic
US Army
McKinsey
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot